Schedule 99.1


OCCULOGIX, INC. FILES REGISTRATION STATEMENT WITH THE U.S. SECURITIES AND
EXCHANGE COMMISSION FOR THE INITIAL PUBLIC OFFERING OF COMMON STOCK

MISSISSAUGA, ONTARIO--(CCNMatthews - Aug. 13, 2004) - OccuLogix, Inc. (formerly
Vascular Sciences Corporation) and its significant stockholder TLC Vision
Corporation announced today that OccuLogix, Inc. has filed a registration
statement with the U.S. Securities and Exchange Commission for the initial
public offering of its common stock. A portion of the shares will be offered by
TLC Vision Corporation and other selling stockholders. The offering is being
underwritten by a syndicate led by Citigroup Global Markets Inc. Other
underwriters included in this offering are SG Cowen & Co. LLC, ThinkEquity
Partners LLC, Orion Securities (USA) Inc. and DeMatteo Monness LLC.

The registration statement has been filed with the Securities and Exchange
Commission but has not yet become effective. These securities may not be sold
nor may offers to buy be accepted prior to the time the registration statement
becomes effective. This press release shall not constitute an offer to sell or
the solicitation of an offer to buy, nor shall there be any sale of these
securities in any State, Province or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such State, Province or other jurisdiction.

Copies of the prospectus, when available, may be obtained from Citigroup Global
Markets Inc. at Brooklyn Army Terminal, 140 58th Street, Brooklyn, NY 11220,
Attn: Prospectus Department, telephone: (718) 765-6732.

OccuLogix, Inc. is an ophthalmic therapeutic company founded in 1996 to
commercialize innovative treatments for eye diseases.

CONTACT:    TLC Vision Corporation
            Stephen Kilmer
            (905) 238-3904

Source: OccuLogix, Inc.